Psilocybin-induced neurocardiogenic syncope: a case report.
Psychopharmacology May 28, 2026 Mazen A Atiq, Eli Weisman, Rodrigo B Guerra et al.
Psilocybin is among the serotonergic psychedelics closest to potential FDA approval, with growing evidence of therapeutic benefit across psychiatric conditions. As clinical trials expand, systematic characterization of adverse events (AEs) remains essential. While transient hypertensive responses are well documented, hypotensive events such as neurocardiogenic syncope (NCS) are rarely reported....